• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Weight-loss: FDA bumps EnteroMedics’ advisory meeting for VBLOC neurostimulation system

Weight-loss: FDA bumps EnteroMedics’ advisory meeting for VBLOC neurostimulation system

March 10, 2014 By Arezu Sarvestani

Weight-loss: FDA moves EnteroMedics' advisory meeting for VBLOC neurostimulation system

Minnesota medical device maker EnteroMedics (NSDQ:ETRM) announced today that its May 2014 date the FDA had been bumped a few months back.

The weight-loss devices maker will now meet with an FDA advisory panel on June 17 for review of its application for VBLOC vagal blocking therapy in treatment of morbid obesity. The prior date, May 29, posed a "significant scheduling conflict" for the federal watchdog agency, EnteroMedics said.

The company is hoping to land the advisory committee’s recommendation for approval of its flagship Maestro implant, which uses mild electrical pulses to stimulate the vagus nerve located between the stomach and the esophagus. Clinical studies have shown that stimulating the vagus nerve may help modify physiological cravings and help patients form better eating habits.

Check out MassDevice’s Q&A with EnteroMedics CEO Mark Knudson and CFO Greg Lea

The panel date is good new for EnteroMedics, which has hit some hurdles on the road to pre-market approval for its landmark device. The FDA last year asked the company to provide more data on its device testing and clinical data, including information on user training and post-approval studies. EnteroMedics said at the time that the additional requests would not hamper its progress or hurt its estimated time-lines.

EnteroMedics submitted its FDA application in June 2013, hoping to land indication to treat obesity, metabolic diseases and other gastrointestinal disorders. The Maestro system has been on the European market since winning CE Mark approval in 2011.

Filed Under: Food & Drug Administration (FDA), Implants, Neuromodulation/Neurostimulation, News Well, Pre-Market Approval (PMA), Weight loss Tagged With: EnteroMedics Inc., Minnesota

More recent news

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Apreo Health emerges from stealth with positive data for lung scaffold
  • Tivic adds new vagus nerve stim patent
  • Study backs Teleflex stapler for reducing post-op GERD rates

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy